Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease [3]

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 623-624

  Carella, Angelo Michele ^a   Biasco, Samantha ^a   Nati, Sandro ^a   Congiu, Angela ^a   Lerma, Enrica ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BILIRUBIN; BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GUANOSINE TRIPHOSPHATE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOGRAFT; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; BONE MARROW BIOPSY; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; ENGRAFTMENT; FLOW CYTOMETRY; GASTROINTESTINAL DISEASE; HLA MATCHING; HUMAN; LARGE CELL LYMPHOMA; LETTER; LIVER DISEASE; MACULOPAPULAR RASH; MALE; MEDIASTINUM MASS; MULTIPLE CYCLE TREATMENT; MYOPATHY; ORAL MUCOSAL DISEASE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEPTICEMIA; SKIN DISEASE; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS REACTIVATION; XEROSTOMIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, B-CELL; MALE; STEROIDS;

EID: 33947675243     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601094362     Document Type: Letter

References (9)

1. Farag, S. S. (2004) Chronic graft-vs.-host disease. Bone Marrow Transplant, 33, pp. 569-577.
2. Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. and Mattes-Ritz, A. (2004) Antibody response to DBY minor histocompatibility antigens is induced after allogeneic stem cell transplantation and in healthy female donors. Blood, 103, pp. 353-359.
3. Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L., Zorn, E. and Lee, S. J. (2005) Andibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-vs.-host disease and disease remission. Blood, 105, pp. 2973-2978.
4. Bacigalupo, A., Lamparelli, T. and Van Lint, M. (2005) Treatment of chronic graft-vs.-host disease with Rituximab. Bone Marrow Transplant, 35, p. S42.
5. Canniga-van, Dijk MR, van der Straaten, H. M., Fijnheer, R., Sanders, C. J., Tweel, J G van den and Verdonck, L. F. (2004) Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-vs.-host disease. Blood, 104, pp. 2603-2606.
6. Ratanatharathorn, V., Carson, E., Reynolds, C., Ayash, L. J., Levine, J. and Yanik, G. (2000) Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-vs.-host disease. Ann Intern Med, 133, pp. 275-279.
7. Ratanatharathorn, V., Ayash, L., Reynolds, C., Silver, S., Reddy, P. and Becker, M. (2003) Treatment of chronic graft-vs.-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant, 9, pp. 505-511.
8. Okamoto, M., Okano, A., Akamatsu, S., Ashihara, E., Inaba, T. and Takenaka, H. (2006) Rituximab is effective for steroid-refractory sclerodermatous chronic graft-vs.-host disease. Leukemia, 20, pp. 172-173.
9. Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S. B. and Bienfang, D. (2006) Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood, 108, pp. 756-762.